<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474017</url>
  </required_header>
  <id_info>
    <org_study_id>MGR001-1010</org_study_id>
    <secondary_id>2015-000463-13</secondary_id>
    <nct_id>NCT02474017</nct_id>
  </id_info>
  <brief_title>An Open Study to Assess the Robustness of the CRC749 Inhaler</brief_title>
  <official_title>An Open Study to Assess the Robustness of the CRC749 Device by Pharmaceutical Performance Following Twice Daily Dosing of MGR001 Administered Via Oral Inhalation in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the robustness of the CRC749 inhaler.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In vitro Measurement of Emitted Dose</measure>
    <time_frame>3 Weeks</time_frame>
    <description>CRC749 inhaler robustness will be assessed by in vitro testing of the CRC749 inhaler after 3 weeks of patient use of the MGR001 product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>MGR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGR001</intervention_name>
    <description>Fluticasone Propionate / Salmeterol administered using CRC749 inhaler</description>
    <arm_group_label>MGR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRC749 inhaler</intervention_name>
    <arm_group_label>MGR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females at least 12 years of age.

          2. A clinical diagnosis for at least 12 weeks prior to screening of asthma or COPD and
             stable treatment.

          3. Spirometry following salbutamol showing FEV1 ≥40% of predicted normal and FEV1/FVC
             ratio &lt;0.7 for COPD subjects.

          4. Spirometry without salbutamol showing FEV1 ≥50% of predicted normal for asthma
             subjects.

          5. Ability to use the CRC749 inhaler.

        Exclusion Criteria:

          1. Other chronic or active respiratory disorder or symptoms of, or treatment for a COPD
             or asthma exacerbation during the 28 days preceding screening.

          2. History of long QT syndrome or screening ECG with QTcF greater than 480 milliseconds.

          3. Current evidence of, or history within the 6 months prior to screening of unstable
             ischemic heart disease, NYHA Class III/IV left ventricular failure, or myocardial
             infarction.

          4. Subjects in whom Advair(R) Diskus(R) / Seretide(R) Accuhaler(R) are contra-indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Allan</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaler</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

